Literature DB >> 15042402

[Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results].

J Wachtlin1, A Wehner, H Heimann, M H Foerster.   

Abstract

BACKGROUND: The aim of this study was the evaluation of safety and effectiveness of photodynamic therapy (PDT) as a treatment option for idiopathic choroidal neovascularization (CNV).
METHODS: We performed a retrospective analysis of 11 eyes of 9 patients who were treated with standard PDT. The follow-up period was at least 1 year and included regular standardized ETDRS visual acuity measurement and fluorescein angiography.
RESULTS: Eight sub- and three juxtafoveal CNV were treated. The mean follow-up was 23.2 months (12-41 months), the mean change in visual acuity was +2.1 lines (+3 for juxtafoveal and +1.9 for subfoveal localization), and a mean of 1.9 (1-3) treatments were performed. Visual acuity improved > or =2 lines in 6 of 11 eyes (54.5%) and 5 eyes (45.5%) remained stable (+/-1 lines). Alterations of the retinal pigmented epithelium (RPE) with window defects in fluorescein angiography occurred in 7 of 11 eyes (63.6%) but did not alter visual acuity. In 4 of 11 cases (36.4%), we saw recurrences after initially successful therapy, which were retreated successfully with PDT.
CONCLUSION: Stabilization or even an improvement of visual acuity in idiopathic CNV is possible with PDT treatment. Side effects such as RPE changes and recurrences are possible, but do not seem to influence visual acuity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042402     DOI: 10.1007/s00347-004-0993-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  20 in total

1.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

2.  Idiopathic focal subretinal neovascularization.

Authors:  G W Cleasby
Journal:  Am J Ophthalmol       Date:  1976-05       Impact factor: 5.258

3.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

4.  Etiology of choroidal neovascularization in young patients.

Authors:  S Y Cohen; A Laroche; Y Leguen; G Soubrane; G J Coscas
Journal:  Ophthalmology       Date:  1996-08       Impact factor: 12.079

5.  A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

Authors:  M Sickenberg; U Schmidt-Erfurth; J W Miller; C J Pournaras; L Zografos; B Piguet; G Donati; H Laqua; I Barbazetto; E S Gragoudas; A M Lane; R Birngruber; H van den Bergh; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler
Journal:  Arch Ophthalmol       Date:  2000-03

6.  Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Authors:  Joachim Wachtlin; Tim Behme; Heinrich Heimann; Ulrich Kellner; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

7.  Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin.

Authors:  Richard F Spaide; Melissa L Martin; Jason Slakter; Lawrence A Yannuzzi; John Sorenson; David R Guyer; K Bailey Freund
Journal:  Am J Ophthalmol       Date:  2002-07       Impact factor: 5.258

8.  The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age.

Authors:  B Lindblom; T Andersson
Journal:  Ophthalmology       Date:  1998-10       Impact factor: 12.079

9.  Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1994-04

10.  Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.

Authors:  David A Saperstein; Philip J Rosenfeld; Neil M Bressler; Robert H Rosa; Michel Sickenberg; Paul Sternberg; Thomas M Aaberg; Thomas M Aaberg; Troy A Reaves
Journal:  Ophthalmology       Date:  2002-08       Impact factor: 12.079

View more
  8 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.

Authors:  Joachim Wachtlin; Andrea Stroux; Andreas Wehner; Heinrich Heimann; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-11       Impact factor: 3.117

3.  [Intravitreal bevacizumab for recurring choroidal neovascularisation].

Authors:  M Niemeyer; L Hefner; C Jochmann; P Wiedemann
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

4.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

5.  [Photodynamic therapy with verteporfin for recurrent choroidal neovascularisation (CNV) following prior argon laser coagulation].

Authors:  A Gabel-Pfisterer; A Wehner; H Heimann; M H Foerster; J Wachtlin
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

6.  Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks.

Authors:  Heinrich Heimann; Faik Gelisken; Joachim Wachtlin; Andreas Wehner; Michael Völker; Michael H Foerster; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-10       Impact factor: 3.117

7.  [Photodynamic therapy with verteporfin for uveal melanoma].

Authors:  J Wachtlin; N E Bechrakis; M H Foerster
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

Review 8.  Photodynamic therapy in macular diseases of asian populations: when East meets West.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Yasuo Tano; David T L Liu; Kenneth K W Li; Dennis S C Lam
Journal:  Jpn J Ophthalmol       Date:  2006 Mar-Apr       Impact factor: 2.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.